Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?

Introduction Thrombophilia (TP) has been proposed as a potential contributor to preeclampsia (PE). However, there is not a clear consensus on testing PE patients for TP due to contradictory evidences on this association. This study aims to identify what conditions of women with PE are associated wit...

Full description

Saved in:
Bibliographic Details
Main Authors: Ana Belén Gálvez MD, Pedro Chorão MD, Ernesto M Talegón MD, María del Carmen Gilabert MD, Amando Blanquer MD, Fernando Ferrando MD, PhD, Ana Cid MD, Antonio Moscardó MD, PhD, Saturnino Haya MD, PhD, Santiago Bonanad MD
Format: Article
Language:English
Published: SAGE Publishing 2025-04-01
Series:Clinical and Applied Thrombosis/Hemostasis
Online Access:https://doi.org/10.1177/10760296251330633
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849316072304410624
author Ana Belén Gálvez MD
Pedro Chorão MD
Ernesto M Talegón MD
María del Carmen Gilabert MD
Amando Blanquer MD
Fernando Ferrando MD, PhD
Ana Cid MD
Antonio Moscardó MD, PhD
Saturnino Haya MD, PhD
Santiago Bonanad MD
author_facet Ana Belén Gálvez MD
Pedro Chorão MD
Ernesto M Talegón MD
María del Carmen Gilabert MD
Amando Blanquer MD
Fernando Ferrando MD, PhD
Ana Cid MD
Antonio Moscardó MD, PhD
Saturnino Haya MD, PhD
Santiago Bonanad MD
author_sort Ana Belén Gálvez MD
collection DOAJ
description Introduction Thrombophilia (TP) has been proposed as a potential contributor to preeclampsia (PE). However, there is not a clear consensus on testing PE patients for TP due to contradictory evidences on this association. This study aims to identify what conditions of women with PE are associated with acquired and hereditary TP, and, additionally, to build a model of TP probability using these characteristics. Material and Methods Retrospective unicentric analysis of women diagnosed with PE referred for TP testing between May 2019 and May 2024. Results In 95 women, 19 (20%) tested positive for TP, of which nine (47%) had antiphospholipid syndrome (APS), six (32%) were heterozygous for PT G20210A, two (11%) had ADAMTS13 deficiency, one (5%) had PS deficiency and one (5%) had heterozygous FV Leiden. In multivariate analysis, intrauterine growth retardation (IUGR; odds ratio (OR) 0.08, 95% confidence interval (CI) 0.01-0.55) and history of previous abortions (OR 0.22, 95%CI 0.06-0.96) were negatively associated with TP. The group of women with both, one or none of those traits showed respectively a TP prevalence of 0%, 15% and 32%. The higher the prevalence of TP, the lower the incidence of placental insufficiency and prematurity ( P  < .05). Conclusions In pregnant women with PE, a history of previous abortions and IUGR were independently associated with the absence of TP. Women without these characteristics would probably benefit most from a Hematology consultation that includes a TP screening. A multinational standard TP screening framework for future studies is warranted to further our understanding of the role of TP in PE and to identify risk-groups for testing.
format Article
id doaj-art-aa48ffc3cb7c4fc2a9f61de950871be3
institution Kabale University
issn 1938-2723
language English
publishDate 2025-04-01
publisher SAGE Publishing
record_format Article
series Clinical and Applied Thrombosis/Hemostasis
spelling doaj-art-aa48ffc3cb7c4fc2a9f61de950871be32025-08-20T03:51:58ZengSAGE PublishingClinical and Applied Thrombosis/Hemostasis1938-27232025-04-013110.1177/10760296251330633Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?Ana Belén Gálvez MD0Pedro Chorão MD1Ernesto M Talegón MD2María del Carmen Gilabert MD3Amando Blanquer MD4Fernando Ferrando MD, PhD5Ana Cid MD6Antonio Moscardó MD, PhD7Saturnino Haya MD, PhD8Santiago Bonanad MD9 Hematology Department, , Valencia, Spain Hematology Research Group, Institut d’Investigació Sanitària La Fe, Valencia, Spain Hematology Department, , Valencia, Spain Hematology Department, , León, Spain Hematology Department, , Valencia, Spain Hematology Department, , Valencia, Spain Hematology Department, , Valencia, Spain Hematology Department, , Valencia, Spain Hematology Department, , Valencia, Spain Hematology Department, , Valencia, SpainIntroduction Thrombophilia (TP) has been proposed as a potential contributor to preeclampsia (PE). However, there is not a clear consensus on testing PE patients for TP due to contradictory evidences on this association. This study aims to identify what conditions of women with PE are associated with acquired and hereditary TP, and, additionally, to build a model of TP probability using these characteristics. Material and Methods Retrospective unicentric analysis of women diagnosed with PE referred for TP testing between May 2019 and May 2024. Results In 95 women, 19 (20%) tested positive for TP, of which nine (47%) had antiphospholipid syndrome (APS), six (32%) were heterozygous for PT G20210A, two (11%) had ADAMTS13 deficiency, one (5%) had PS deficiency and one (5%) had heterozygous FV Leiden. In multivariate analysis, intrauterine growth retardation (IUGR; odds ratio (OR) 0.08, 95% confidence interval (CI) 0.01-0.55) and history of previous abortions (OR 0.22, 95%CI 0.06-0.96) were negatively associated with TP. The group of women with both, one or none of those traits showed respectively a TP prevalence of 0%, 15% and 32%. The higher the prevalence of TP, the lower the incidence of placental insufficiency and prematurity ( P  < .05). Conclusions In pregnant women with PE, a history of previous abortions and IUGR were independently associated with the absence of TP. Women without these characteristics would probably benefit most from a Hematology consultation that includes a TP screening. A multinational standard TP screening framework for future studies is warranted to further our understanding of the role of TP in PE and to identify risk-groups for testing.https://doi.org/10.1177/10760296251330633
spellingShingle Ana Belén Gálvez MD
Pedro Chorão MD
Ernesto M Talegón MD
María del Carmen Gilabert MD
Amando Blanquer MD
Fernando Ferrando MD, PhD
Ana Cid MD
Antonio Moscardó MD, PhD
Saturnino Haya MD, PhD
Santiago Bonanad MD
Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
Clinical and Applied Thrombosis/Hemostasis
title Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
title_full Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
title_fullStr Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
title_full_unstemmed Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
title_short Predicting Thrombophilia in Preeclampsia: Is Universal Testing Necessary?
title_sort predicting thrombophilia in preeclampsia is universal testing necessary
url https://doi.org/10.1177/10760296251330633
work_keys_str_mv AT anabelengalvezmd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT pedrochoraomd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT ernestomtalegonmd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT mariadelcarmengilabertmd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT amandoblanquermd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT fernandoferrandomdphd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT anacidmd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT antoniomoscardomdphd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT saturninohayamdphd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary
AT santiagobonanadmd predictingthrombophiliainpreeclampsiaisuniversaltestingnecessary